Dr Nai Hua Shu, MD | |
1600 Lebanon Ave, Suite 101, Belleville, IL 62221-2491 | |
(618) 239-6269 | |
Not Available |
Full Name | Dr Nai Hua Shu |
---|---|
Gender | Male |
Speciality | General Practice |
Experience | 37 Years |
Location | 1600 Lebanon Ave, Belleville, Illinois |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073522249 | NPI | - | NPPES |
08222941 | Other | IL | BCBS OF ILLINOIS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | MD 103976 (Missouri) | Secondary |
208D00000X | General Practice | (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Nai Hua Shu, MD 3206 Clifton Ave Apt B, Saint Louis, MO 63139-2363 Ph: (314) 647-5678 | Dr Nai Hua Shu, MD 1600 Lebanon Ave, Suite 101, Belleville, IL 62221-2491 Ph: (618) 239-6269 |
News Archive
Six years ago, Michael Niederweis, Ph.D., described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis.
The Botswana-Baylor Children's Clinical Center of Excellence recently provided home-based HIV tests to orphans and vulnerable children, as well as their parents and caretakers, in Gaborone, Botswana, the Mmegi reports.
Although flu and pneumonia can be lethal for cancer patients, more than one quarter of patients undergoing radiation therapy are not complying with national guidelines to be vaccinated against these potentially life-threatening yet preventable illnesses, according to a study presented October 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
VirMedica, a leading provider of technology solutions designed to optimize the commercialization of specialty pharmaceutical products, announced today that VirMedica, Inc. has acquired the assets of TransEngen, Inc. The $15 million dollar financing was led by Nashville-based Petra Capital Partners along with Menlo Park-based HealthQuest Capital.
VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of this study is to determine if Onrigin™ plus LDAC improves overall survival compared with LDAC alone.
› Verified 6 days ago
Dr. Glen S Babich, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 813 Stone Creek Ln, Belleville, IL 62223 Phone: 615-973-0026 Fax: 618-213-7168 | |
Dr. Craig S Vinch, MD General Practice Medicare: Medicare Enrolled Practice Location: 340 W Lincoln St, Ste. 400, Belleville, IL 62220 Phone: 618-233-6044 Fax: 618-233-5195 | |
Dr. John J Boeren, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 311 W Lincoln St, Suite 300, Belleville, IL 62220 Phone: 618-234-2566 Fax: 618-234-5650 |